Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0ZXRLG)
| ADC Name |
SLV-154
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
SLV-154
Click to Show/Hide
|
|||||
| Organization |
Solve Therapeutics (Originator)
|
|||||
| Drug Status |
Phase 1
|
|||||
| Antibody Name |
Undisclosed
|
Antigen Name |
Undisclosed
|
|||
| Payload Name |
Undisclosed
|
|||||
| Payload Target |
Undisclosed
|
|||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Undisclosed
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Disease Name | Phase 1 | Phase 2 | Phase 3 | Approved |
|---|---|---|---|---|
| Sarcoma | ||||
| Lung cancer | ||||
| Breast cancer | ||||
| Ovarian cancer | ||||
| Endometrial cancer | ||||
| Cervical cancer | ||||
| Urothelial cancer | ||||
| Thyroid cancer | ||||
| Head and neck cancer |